S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Public Service Announcement: New National Emergency Incoming (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Better Than Oil Stocks (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Better Than Oil Stocks (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Public Service Announcement: New National Emergency Incoming (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Better Than Oil Stocks (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Better Than Oil Stocks (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Public Service Announcement: New National Emergency Incoming (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Better Than Oil Stocks (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Better Than Oil Stocks (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Public Service Announcement: New National Emergency Incoming (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Better Than Oil Stocks (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Better Than Oil Stocks (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024

Dyne Therapeutics (DYN) Competitors

$22.79
+0.38 (+1.70%)
(As of 02/23/2024 ET)

DYN vs. PCRX, ABCL, KNSA, AKRO, SAGE, VRNA, MRVI, MIRM, PRTA, and XNCR

Should you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include Pacira BioSciences (PCRX), AbCellera Biologics (ABCL), Kiniksa Pharmaceuticals (KNSA), Akero Therapeutics (AKRO), Sage Therapeutics (SAGE), Verona Pharma (VRNA), Maravai LifeSciences (MRVI), Mirum Pharmaceuticals (MIRM), Prothena (PRTA), and Xencor (XNCR). These companies are all part of the "pharmaceutical preparations" industry.

Dyne Therapeutics vs.

Pacira BioSciences (NASDAQ:PCRX) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings, community ranking and analyst recommendations.

Pacira BioSciences received 797 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. Likewise, 71.67% of users gave Pacira BioSciences an outperform vote while only 45.45% of users gave Dyne Therapeutics an outperform vote.

CompanyUnderperformOutperform
Pacira BioSciencesOutperform Votes
802
71.67%
Underperform Votes
317
28.33%
Dyne TherapeuticsOutperform Votes
5
45.45%
Underperform Votes
6
54.55%

99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 6.6% of Pacira BioSciences shares are owned by insiders. Comparatively, 32.9% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Pacira BioSciences has a net margin of 1.05% compared to Pacira BioSciences' net margin of 0.00%. Dyne Therapeutics' return on equity of 12.16% beat Pacira BioSciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Pacira BioSciences1.05% 12.16% 6.16%
Dyne Therapeutics N/A -97.57%-79.16%

Pacira BioSciences currently has a consensus target price of $51.44, suggesting a potential upside of 71.25%. Dyne Therapeutics has a consensus target price of $33.50, suggesting a potential upside of 46.99%. Given Dyne Therapeutics' higher probable upside, research analysts plainly believe Pacira BioSciences is more favorable than Dyne Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pacira BioSciences
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
3.00
Dyne Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25

In the previous week, Dyne Therapeutics had 11 more articles in the media than Pacira BioSciences. MarketBeat recorded 27 mentions for Dyne Therapeutics and 16 mentions for Pacira BioSciences. Dyne Therapeutics' average media sentiment score of 0.20 beat Pacira BioSciences' score of 0.06 indicating that Pacira BioSciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pacira BioSciences
6 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Dyne Therapeutics
4 Very Positive mention(s)
2 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Pacira BioSciences has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.

Pacira BioSciences has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacira BioSciences$666.82M2.09$15.91M$0.09333.78
Dyne TherapeuticsN/AN/A-$168.10M-$3.59-6.35

Summary

Pacira BioSciences beats Dyne Therapeutics on 13 of the 18 factors compared between the two stocks.


Get Dyne Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DYN vs. The Competition

MetricDyne TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.40B$6.83B$5.07B$7.52B
Dividend YieldN/A2.85%2.86%3.87%
P/E Ratio-6.3514.91226.0117.61
Price / SalesN/A146.413,014.2255.10
Price / CashN/A18.6090.2152.46
Price / Book4.714.584.364.64
Net Income-$168.10M$162.41M$112.62M$207.29M
7 Day Performance-0.52%0.96%0.93%-1.13%
1 Month Performance34.38%10.81%7.29%3.57%
1 Year Performance96.47%4.28%10.65%5.54%

Dyne Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PCRX
Pacira BioSciences
4.2984 of 5 stars
$29.70
-0.5%
$51.44
+73.2%
-28.0%$1.38B$666.82M330.00715Upcoming Earnings
Analyst Revision
News Coverage
ABCL
AbCellera Biologics
1.585 of 5 stars
$4.81
-9.4%
$20.00
+315.8%
-42.8%$1.40B$485.42M-10.69630Analyst Report
Analyst Revision
News Coverage
High Trading Volume
KNSA
Kiniksa Pharmaceuticals
1.7148 of 5 stars
$19.96
+0.2%
$22.50
+12.7%
+49.7%$1.40B$220.18M-181.44220Upcoming Earnings
Positive News
AKRO
Akero Therapeutics
3.9234 of 5 stars
$24.04
+11.2%
$40.86
+70.0%
-43.1%$1.34BN/A-10.2351Positive News
SAGE
Sage Therapeutics
3.5584 of 5 stars
$22.20
+0.1%
$41.59
+87.3%
-47.1%$1.33B$86.46M-2.45689
VRNA
Verona Pharma
0.3149 of 5 stars
$16.59
-2.4%
$32.60
+96.5%
-23.1%$1.33B$460,000.00-24.0435Upcoming Earnings
News Coverage
MRVI
Maravai LifeSciences
4.3312 of 5 stars
$5.26
-1.1%
$13.22
+151.4%
-44.1%$1.32B$883M29.22670Analyst Report
Options Volume
News Coverage
Gap Up
MIRM
Mirum Pharmaceuticals
3.8646 of 5 stars
$28.29
-2.8%
$54.13
+91.3%
+17.9%$1.32B$77.06M-6.58249
PRTA
Prothena
3.8785 of 5 stars
$27.05
-1.7%
$69.89
+158.4%
-46.5%$1.45B$91.37M-9.66127Analyst Report
Analyst Revision
Gap Down
XNCR
Xencor
3.6385 of 5 stars
$24.09
+2.5%
$40.38
+67.6%
-28.4%$1.47B$164.58M-12.11281Analyst Upgrade
Positive News
Gap Down

Related Companies and Tools

This page (NASDAQ:DYN) was last updated on 2/24/2024 by MarketBeat.com Staff